U1 and systemic sclerosis: Sobanski et al. found that, among SSc-PAH groups, patients with anti-U1 RNP antibodies were younger at diagnosis and had better mean predicted DLCO; also, a larger proportion of them were in WHO functional classes I and II compared to those without anti-U1 RNP antibodies.